New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2013
11:18 EDTCSTR, EXC, RPRX, ACAD, HLFOptions with increasing implied volatility: HLF RPRX CSTR ACAD EXC
News For HLF;RPRX;CSTR;ACAD;EXC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 29, 2015
10:51 EDTEXCSupreme Court overrules EPA regulations on power plant pollution, The Hill says
Subscribe for More Information
09:04 EDTHLFHerbalife says Eric D. Rosen will join company as VP of government relations
Herbalife announced that Eric D. Rosen will join Herbalife’s growing global corporate affairs team as VP of government relations and director of its Washington, D.C. office. Rosen will oversee Herbalife’s D.C. operations and will report to Ric Hobby, who was recently appointed as head of Herbalife’s global government relations reporting to Alan Hoffman, executive VP of the global corporate affairs team. Rosen, who will be based out of Herbalife’s D.C. office, is a Capitol Hill veteran with experience in the Senate, House, and Executive Branch.
June 26, 2015
13:09 EDTHLFPershing Square urges Herbalife CEO to release video referenced by NY Post
Pershing Square Capital released a letter it sent to Herbalife CEO Michael Johnson concerning his "serious admissions about Herbalife and its conduct that were revealed by the New York Post." The letter states in part: "Today the New York Post reported on a 71-minute video in which you appear on a stage, making serious admissions about Herbalife and its conduct...We urge that you release the 71-minute video and any similar materials in your possession or control, and we encourage Herbalife employees, distributors and others with similar materials to come forward...In February 2013, we publicly asked you to provide simple data on how many people arrive and leave at each level of Herbalife’s network over time...You still have not disclosed the facts. In light of your admission that Herbalife is a lottery ticket, basic fairness suggests you should disclose the facts."
10:14 EDTACADOptions with decreasing implied volatility
Subscribe for More Information
10:00 EDTEXCConstellation selected by City of Cleveland for electricity supply
Subscribe for More Information
08:56 EDTHLFVideo shows Herbalife CEO saw ‘pyramiding’ signs in 2005, NY Post reports
Subscribe for More Information
June 25, 2015
10:07 EDTHLFHerbalife rises after Pivotal says SEC completes review of filings
Subscribe for More Information
09:47 EDTHLFHerbalife price target raised to $90 from $80 at Pivotal Research
Subscribe for More Information
June 22, 2015
19:56 EDTEXCUtilities sector dips after EPA warns of 'significant risks' from climate change
Subscribe for More Information
June 16, 2015
09:02 EDTACADACADIA says Nuplazid 'generally safe, well tolerated' in PD patients
ACADIA Pharmaceuticals announced the presentation of integrated efficacy and tolerability data from its Phase III program with NUPLAZID at the 19th International Congress of Parkinson’s Disease and Movement Disorders held in San Diego. “Data from the integrated analysis of Phase III studies continue to support the potential for NUPLAZID to safely and effectively treat Parkinson’s disease psychosis, a condition for which there is no approved therapy in the United States,” said Roger Mills, M.D., Executive Vice President, Development and Chief Medical Officer. “Furthermore, data from our open-label safety extension studies indicate that long-term administration of NUPLAZID is generally safe and well tolerated in patients with Parkinson’s disease psychosis and that duration of antipsychotic effect may be maintained for longer than the six weeks investigated in our Phase III placebo-controlled efficacy studies.” An integrated analysis was performed on efficacy and tolerability data from two six-week Phase III placebo-controlled clinical trials with NUPLAZID in Parkinson’s disease psychosis. In this large pooled sample of 268 patients from North America, NUPLAZID showed highly significant improvement in psychosis compared to placebo on the 9-item SAPS-PD scale. NUPLAZID demonstrated significant improvement on each of the separate hallucinations and delusions domains and also on secondary psychoses measures, including the Clinical Global Impression-Improvement and the Clinical Global Impression-Severity scales. In addition, NUPLAZID demonstrated significant improvement on nighttime sleep, daytime wakefulness and caregiver burden, representing additional potential clinically impactful benefits. Results were consistent across all subgroups of interest, showing greater improvement with NUPLAZID over placebo regardless of age, sex, race group or MMSE screening score. Pooled analysis of data from all Phase III placebo-controlled clinical trials with NUPLAZID showed that NUPLAZID was well tolerated and had no impairment on motor function. The adverse event profile of NUPLAZID was similar to placebo.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use